Clinical Trial Results:
The efficacy of Indwelling Pleural Catheter placement versus IPC placement PLUS sclerosant (talc) in patients with malignant pleural effusions managed exclusively as out-patients
Summary
|
|
EudraCT number |
2012-000599-40 |
Trial protocol |
GB |
Global end of trial date |
09 Dec 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 May 2018
|
First version publication date |
12 May 2018
|
Other versions |
|
Summary report(s) |
supplementary material for publication protocols and analysis plans IPC-Plus NEJM paper |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2795
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN73255764 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
North Bristol NHS Trust
|
||
Sponsor organisation address |
Southmead Hospital, Bristol, United Kingdom,
|
||
Public contact |
Trial manager, Respiratory Research, North Bristol NHS Trust, emma.keenan@nbt.nhs.uk
|
||
Scientific contact |
Trial coordinator, Academic Respiratory Unit, University of Bristol, rahul.bhatnagar@bristol.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Dec 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Dec 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Dec 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The IPC-PLUS trial is a study to help determine the best way to manage patients who develop fluid around the lung as a result of cancer (malignant pleural effusion). The aim is to compare outcomes in two groups of patients. The first group will be treated with an indwelling pleural catheter (IPC, or tunnelled chest tube) to help drain away the fluid, and will then be given an inert placebo substance (saline) into the drain before being followed up. The second group will receive the same type of IPC to drain away the fluid, but will then be given an injection of sterile talc powder into the drain instead of placebo. Our primary objective is to determine whether introducing talc through the IPC leads to an improved rate of successful pleurodesis, whereby the two linings of the lung are stuck together to prevent further fluid build-up. This is a randomised controlled trial, which means patients will be randomly allocated to receive either the placebo injection or the talc injection
|
||
Protection of trial subjects |
The study was reviewed and approved by an approved NHS ethics committee and by the MHRA
Patients were seen on a frequent basis (every 2 weeks)
An emergency phone number was provided to all participants and was available at all times
|
||
Background therapy |
Insertion of an indwelling pleural catheter for the management of malignant pleural effusion | ||
Evidence for comparator |
Talc is the gold-standard pleurodesis agent used widely around the world. The dose and administration method for talc was matched to current UK standards. Saline was chosen as a comparator as there is no evidence that this has the ability to induce pleurodesis. | ||
Actual start date of recruitment |
28 May 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 154
|
||
Worldwide total number of subjects |
154
|
||
EEA total number of subjects |
154
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
56
|
||
From 65 to 84 years |
90
|
||
85 years and over |
8
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
18 sites from England and Scotland. Recruitment took place from June 2012 to September 2016 | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Patients with malignant pleural effusion suitable for IPC insertion identified from routine practice. Not eligible if pre-existing contraindication to pleurodesis (e.g. trapped lung) or if unable to comply with trial schedule | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Day 10 randomisation
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Single blind | ||||||||||||||||||
Roles blinded |
Subject | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Intervention | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Talc
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Novatech Steritalc
|
||||||||||||||||||
Pharmaceutical forms |
Powder for suspension for injection
|
||||||||||||||||||
Routes of administration |
Intrapleural use
|
||||||||||||||||||
Dosage and administration details |
4 grams made into slurry with 50mls normal saline
|
||||||||||||||||||
Arm title
|
Control | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
0.9% saline solution
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||||||||||||||
Routes of administration |
Intrapleural use
|
||||||||||||||||||
Dosage and administration details |
50mls total
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Follow-up over 10 weeks
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Intervention | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Talc
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Novatech Steritalc
|
||||||||||||||||||
Pharmaceutical forms |
Powder for suspension for injection
|
||||||||||||||||||
Routes of administration |
Intrapleural use
|
||||||||||||||||||
Dosage and administration details |
4 grams made into slurry with 50mls normal saline
|
||||||||||||||||||
Investigational medicinal product name |
0.9% saline solution
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||||||||||||||
Routes of administration |
Intrapleural use
|
||||||||||||||||||
Dosage and administration details |
50mls total
|
||||||||||||||||||
Arm title
|
Control | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
0.9% saline solution
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||||||||||||||
Routes of administration |
Intrapleural use
|
||||||||||||||||||
Dosage and administration details |
50mls
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intervention
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Control
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intervention
|
||
Reporting group description |
- | ||
Reporting group title |
Control
|
||
Reporting group description |
- | ||
Reporting group title |
Intervention
|
||
Reporting group description |
- | ||
Reporting group title |
Control
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Pleurodesis success at 5 weeks | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
5 weeks post randomisation
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary outcome | ||||||||||||
Comparison groups |
Intervention v Control
|
||||||||||||
Number of subjects included in analysis |
139
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.008 | ||||||||||||
Method |
competing-risk time-to-event regression | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
2.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.23 | ||||||||||||
upper limit |
3.92 |
|
|||||||||||||
End point title |
Pleurodesis success at 10 weeks | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
10 weeks post randomisation
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Pleurodesis success at 5 weeks (alternative) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
5 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Pleurodesis success at 10 weeks (alternative) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
10 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Volume of fluid over 10 weeks | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Over 10 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Additional procedures | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Over 10 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
From consent to trial exit
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
Locally determined | ||
Dictionary version |
n/a
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: All data regarding adverse events is available in the summary documents attached to this submission. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
09 Jul 2012 |
Clarification of randomisation target of 154 patients
• All references to SF-36 QoL questionnaire removed
• Added exclusion criteria: patients must have access to phone for investigator trial contact
• Clarified sample collection and analysis
• Clarified procedure pre-randomisation
• Clarified that patients may also be excluded from randomisation for clinical reasons other than x-ray appearances
• Updated summary tables and clarified pre-randomisation day nomenclature
• Stipulated a time window in which patients must have first IPC drainage post-randomisation
• Clarified time window in which pts may have follow-up appointments
• Clarified wording in safety reporting section and highlighted expected minor side effects from talc
• Updated members of trial steering committee
• New sites added: Preston, Portsmouth, Bristol Royal Infirmary |
||
18 Dec 2012 |
New sites added: Worcester, North Staffordshire, North Tyneside, Middlesbrough, South Manchester and Blackpool
• Creation of letter and short trial summary for district nurses
• Alteration to primary endpoint, changing minimal fluid volume required for pleurodesis from 20mLs to 50mLs
• Change to time limit given to patients to consider PIS
• Removed requirement that trial CXR must be taken posterior-anterior (PA) specifically
• Trial flow chart updated allowed patients to have follow up appointments at satellite centres
• Allowance for patients to be approached as an inpatient but management must be as an outpatient for trial
• Clarifications to adverse event and serious adverse event reporting procedures |
||
01 Aug 2013 |
New sites added: London, Mansfield, Stockton-on-Tees and Sheffield
• Clarification of wording of primary endpoint, removal of duplicate secondary endpoint and addition of new secondary endpoint
4.0
01/08/2013
47
• Clarification of definition of trapped lung in trial flow chart and protocol
• Addition of new QoL questionnaire (QLQ-C30) for all new trial participants
• Expanded the use of pleural manometry to all centres
• Removed need for 0.9% saline placebo to be sources from particular manufacturer
• Updated wording of how the primary outcome will be analysed
• Updated membership of trial steering committee |
||
01 Jan 2014 |
New sites added: Northampton, Ayr, Cambridge, and Aintree
• Change of inclusion criteria to require WHO performance of 2 or better to be eligible. 3 if goes to 2 after drainage.
• Allow pts with previous pleurodesis as long as more than 56 days before trial entry
• Relax follow-up visits by allowing day 42 and 56 to be carried out over telephone
• Allow carers/relatives to perform chest drains after day 28 post randomisation visit
• Extend recruitment period to May 2015
• Relaxation of manometry recordings from every 100 ml to every 100-200 ml
• Updated membership of TSC |
||
09 Sep 2016 |
Remove interim analysis
• add cough, chest pain/discomfort following drainage to expected AEs
• amend reporting procedure for mild cough, chest pain/discomfort
• extend trial end date to 31/10/2016
• update R&I contact details for SAE reporting |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Only primary endpoint and major secondary endpoints are summarised here. For complete trial data and details of analyses, adverse events and all amendments, please refer to attachments. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/29617585 |